Collaborative study for HyperglycemIc patients by Pitavastatin INtervention

Collaborative study for HyperglycemIc patients by Pitavastatin INtervention - Collaborative study for HyperglycemIc patients by Pitavastatin INtervention(CHIP-IN)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004834

Enrollment

100

Registered

2011-01-07

Start date

2011-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypercholesterolemiac patients with diabetes mellitus

Interventions

Sitagliptin + Pitavastatin Sitagliptin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hypercholesterolemic patients with diabetes mellitus with diabetes mellitus (1) Patients who has administered sitagliptin for more than 12 weeks (2) Patients whose HbA1c is stable between 5.8% and 8.0% during 12-week sitagliptin therapy (3) Patients whose LDL-C is between 120 mg/dL and 160 mg/dL (4) Patients who voluntarily provide informed consent with sufficient comprehension after receiving sufficient explanation of this study

Exclusion criteria

Exclusion criteria: (1) Patients under insulin treatment (2) Patients with history of cardiovascular events (ischemic heart disease, cerebral vascular disease, etc.) (3) CK (CPK) > upper limit of normal (ULN) (4) AST (GOT) and ALT (GPT) > 3 times ULN (5) Serum creatinine > 1.5 mg/dL for male, 1.3 mg/dL for female, eGFR < 50 ml/min/1.73 m2 (6) Patients judged to be inappropriate for this study by the investigators (7) Under 20 years old

Design outcomes

Primary

Measure	Time frame
Changes of HbA1c from the baseline to 24 weeks	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026